Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer

Study:

Phase II Study of Carboxyamidotriazole (CAI, NSC #609974) in Patients With Advanced Renal Cell Carcinoma Refractory to Immunotherapy

Rationale:

Carboxyamidotriazole may stop the growth of kidney cancer by stopping blood flow to the tumor.

Purpose:

Phase II trial to study the effectiveness of carboxyamidotriazole in treating patients who have advanced kidney cancer that has not responded to biological therapy.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Kidney Cancer Drug: carboxyamidotriazole Phase 2

Verified by Eastern Cooperative Oncology Group December, 2005

Sponsored by: Eastern Cooperative Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00005045

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Cleveland Clinic Cancer Center
Cleveland, Ohio 44195
United States

David Friedland, MD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site